Rubric Capital Management (New York)’s Arcutis Biotherapeutics ARQT Stock Holding History

Rubric Capital Management (New York)’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$217M	Hold	8,271,577	–	–	1.99%	13
2026 Q1	$195M	Hold	8,271,577	–	–	2.06%	11
2025 Q4	$240M	Sell	8,271,577 -2,477,880	-23%	-$63.4M	2.87%	7
2025 Q3	$203M	Hold	10,749,457	–	–	2.29%	9
2025 Q2	$151M	Sell	10,749,457 -217,215	-2%	-$3.05M	2.28%	11
2025 Q1	$172M	Hold	10,966,672	–	–	3.07%	8
2024 Q4	$153M	Hold	10,966,672	–	–	1.96%	11
2024 Q3	$102M	Buy	10,966,672 +1,150,000	+12%	+$11.3M	1.66%	11
2024 Q2	$91.3M	Buy	9,816,672 +2,306,672	+31%	+$20.9M	2.39%	12
2024 Q1	$74.4M	Buy	7,510,000 +865,470	+13%	+$6.46M	2.2%	13
2023 Q4	$21.5M	Buy	6,644,530 +1,610,000	+32%	+$4.38M	0.45%	37
2023 Q3	$26.7M	Buy	5,034,530 +150,000	+3%	+$1.28M	1%	31
2023 Q2	$46.5M	Buy	4,884,530 +1,384,530	+40%	+$15.4M	1.99%	21
2023 Q1	$38.5M	Buy	3,500,000 +757,481	+28%	+$11M	1%	28
2022 Q4	$40.6M	Buy	2,742,519 +2,270,472	+481%	+$39.7M	1.77%	21
2022 Q3	$9.02M	Buy	472,047 +245,701	+109%	+$5.57M	0.45%	47
2022 Q2	$4.82M	Buy	+226,346	New	+$4.64M	0.25%	62

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Rubric Capital Management (New York)'s ARQT Position: Q2 2026 in Review

Rubric Capital Management (New York) held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 8,271,577 shares worth $217M. The position accounts for 1.99% of the portfolio, ranked #13.

Rubric Capital Management (New York) first reported a position in ARQT in Q2 2022 and has held it in 17 quarters since. The position peaked at $240M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Rubric Capital Management (New York) held 8,271,577 shares of Arcutis Biotherapeutics worth $217M as of Q2 2026.
Rubric Capital Management (New York) left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
Arcutis Biotherapeutics made up 1.99% of Rubric Capital Management (New York)'s portfolio in Q2 2026, its #13 holding.
Rubric Capital Management (New York) first reported a position in Arcutis Biotherapeutics in Q2 2022 and has held it in 17 quarters since.
Rubric Capital Management (New York)'s Arcutis Biotherapeutics position peaked at $240M in Q4 2025.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2026, filed 14 Aug 2026.